Strains from the species Bifidobacterium breve have been extensively characterized for potential probiotic properties and several strains have been formulated for clinical trials as single probiotic organisms, in conjunction with a prebiotic and in association with other probiotic strains. Based on in vitro and in vivo properties demonstrated in the laboratory, B. breve strains have been evaluated, in particular, in allergic disorders and in necrotizing enterocolitis with variable results. As is the case with all probiotic organisms, beneficial laboratory and clinical effects are strictly strain specific.

Original languageEnglish (US)
Title of host publicationThe Microbiota in Gastrointestinal Pathophysiology
Subtitle of host publicationImplications for Human Health, Prebiotics, Probiotics, and Dysbiosis
Number of pages3
ISBN (Electronic)9780128040621
ISBN (Print)9780128040249
StatePublished - Jan 1 2017


  • Allergy
  • B632
  • BB536
  • BR-03
  • Bifidobacterium breve strains BBG-001
  • C-50 and Yakult
  • CNCM I-4035
  • Immunomodulation
  • M-16V
  • Necrotizing enterocolitis

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Bifidobacterium breve'. Together they form a unique fingerprint.

Cite this